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Cell surface molecules that regulate antigen-dependent signaling of T cells have
been the focus ofmuch investigation. Datahave emerged indicating that the clono-
typic a/0 heterodimer, expressed on the surface of T cells in association with the
lineage-specific CD3-protein complex, recognizes antigen in the context of MHC
gene products expressedonthe surface ofantigen-presenting (accessory) cells (1-5).
Additional T cell surface molecules, the CD41 and the CD8 antigens, appear to con-
tribute to the Tcell activation process by functioning as associative recognition/re-
striction elements for the monomorphic component of MHC antigens. Although
the CD2 antigen has also been implicated in many aspects of T cell functions, its
role in T cell activation initiated via the CD3/TCRa/(3 is controversial (6-12).
The studies reported herewere prompted byouroriginal demonstration ofdifferen-
tial effects ofmAb directed at the SRBC-binding epitope of the CD2 antigen. We
found that the anti-CD2 mAb prevents clusteringbetween Tcells and aB-lympho-
blastoid cell line (B-LCL)' endowed with accessory cell activity, and inhibits T cell
proliferation dependent on co-stimulatory signals provided by the B-LCL but not
with 12-o-tetradecanoyl phorbol-13-acetate. Interestingly, the same anti-CD2 mAb,
when crosslinked, was an effective substitute for accessory cell signals in the activa-
tion ofnormal human quiescent T cells (13, 14). Because these observations raised
the possibility that the CD2 antigen might participate in physiological T cell-acces-
sory cell interactions and because activation via the a/a heterodimer of the TCR
is dependent upon accessorycell signals(15-17), we reasoned, despite previous sug-
gestionsby others ofmutually antagonistic signalingviathe TCR complexand CD2
antigen (9-11), that signaling via the TCR and the CD2 antigen would be syner-
gistic inpromotingT cell activation. Herewe havetested thishypothesis usinghighly
purified normal human T cells and T cell subsets (CD4+ or CD8+ T cells), and
mAbs directed at the CD3/TCR-a/0 and at the CD2 antigen, as probes.
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Results from our investigation demonstrate explicitly that signals initiated by cross-
linking the TCR complex with the CD2 antigen activates normal human T cells
(CD4+ or CD8+ T cells) . Furthermore, this novel model of activation is homolo-
gous to physiologic antigenic signaling of T cellswith respect to signal transduction
via Cat + mobilization and protein kinase C activation, transcriptional activation,
and translation of the gene for IL-2, and the utilization ofIL-2-IL-2 receptor pathway
for T cell proliferation.
Materials and Methods
Materials.
￿
mAbs directed at a framework determinant of CD3/TCR-a//3, anti-TCR-1
(15-17), anti-Leu-5b (CD2), anti-Leu-3a +3b (CD4), anti-Leu-1 (CD5), anti-Leu-M3 (CD14),
anti-Leu-Ml (CD15), anti-IL-2 receptor a (CD25), and anti-HLA-DR were purchased from
Becton Dickinson & Co., Mountain View, CA. OKTIl (CD2), OKT4 (CD4), and OKT4A
(CD4) mAbs were purchased from Ortho Pharmaceuticals, Raritan, NJ. M02 (CD14) and
NKH-1A (CD56) mAbs were purchased from Coulter Corp., Hialeah, FL. Affinity-purified
goat antibodies specific for mouse IgG and affinity-purified goat antibodies specific for y-1
or -y-2a heavy chains were purchased from Southern Biotechnology Associates, Inc., Bir-
mingham, AL. Staurosporine and K-252a were purchased from Kyowa Hakko USA Inc.,
NewYork, NY, and 1-5 (isoquinolinylsulfonyl)-2-methyl-piperazine (compound H-7) was from
Sigma Chemical Co., St. Louis, MO.
Generation and Purification of F(ab')2 Fragments of mAbs.
￿
An immunopure F(ab')2 prepara-
tion kit (Pierce Chemical Co., Rockford, IL) was used for the generation and purification
of F(ab')2 fragment of anti-TCR-1 or OKTII. In brief, the mAbs were dialyzed against 20
mM sodium acetate (pH 4.5) and concentrated. F(ab)2 fragments were generated using im-
mobilized pepsin and a digestion buffer (0.1 M sodium citrate buffer, pH 4.1 and 60-min
incubation for IgG2a OKTll and pH 3 .5 and 8-h incubation for IgGI antiTCR1). The
F(ab')2 fragments were purified with an immobilized protein A column using immunopure
binding and elution buffers (Pierce Chemical Co.). The eluted fragments were dialyzed against
PBS (pH 7.4) for 24 h using dialysis tubing of 50,000 molecular weight cut off, and concen-
trated. SDS-PAGE of eluted fragments under nonreducing conditions demonstrated the pres-
ence of F(ab')2 fragments and the absence of intact IgG mAbs.
Affinity-purified F(ab')2 fragments of rabbit antibodies specific for mouse IgG, purchased
from Southern Biotechnology Associates, were used to crosslink the F(ab)2 fragments of anti-
TCR1, OKTII, or antiTCR1 and OKTII.
Isolation of Tcells and Subsets ofTCells.
￿
Human PBMC were isolated by Ficoll-Paque (Phar-
macia Fine Chemicals, Piscataway, NJ) density gradient centrifugation of venous blood ob-
tained from healthy normal individuals. T cells were isolated from PBMC with a previously
described sequential multi-step procedure (18) that includes: (a) depletion of adherent cells
by Sephadex-G10 (Pharmacia) gel filtration; (b) depletion ofresidual monocytes by treatment
with 5 MM t.-leucine methyl ester (Sigma Chemical Co., St. Louis, MO); (c) depletion of
HLA-DR' cells and NK cells by treatment with anti-HLA-DR mAb, anti-NKH-IA mAb,
and prescreened rabbit complement; and (d) utilization of the SRBC-rosetting technique
as the final preparative step for the isolation ofhighly purified T cells. FAGS analysis ofcells
isolated revealed >98% of cells to be positive for CD3 and CD2 antigens and <1% of cells
to be positive for NKH-1, HLA-DR, CD14, CD19, or CD25 antigen.
The CD4* and the CD8+ T cell subsets were isolated with a modified panning procedure
of Wysocki and Sato (19). In brief, highly purified T cells were pretreated with saturating
concentrations of anti-CD8 mAb (OKT8 and anti-Leu-2A) or anti-CD4 mAbs (OKT4A
and OKT4) and then placed into petri dishes coated with affinity-purified goat anti-mouse
IgG and incubated for 70 min at 41C. Nonadherent cells (negative selection) were removed
following the incubation period. FACS analyses of negatively selected CD4+ or CD8* T cell
subset revealed >95 17o purity for the corresponding phenotype, and <1% contamination with
the reciprocal subset or with NKH-1, HLA-DR, CD14, CD19, or CD25 antigen positive cells.SUTHANTHIRAN
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Measurement of T CellActivation.
￿
IL-2 receptora (CD25) expression was measured by FAGS
analysis using Epics C cell sorter (Coulter Corp.), as described (18). The cells were labeled
with PE-conjugated anti-CD25 mAb and the percentage of cells expressing IL-2 receptor
a was determined by analysis of immunofluorescence histograms, with Epics C multidata
acquisition and display systems, software version 3.1. PE-conjugated isotypic control mAb
was used to determine nonspecific fluorescence signal.
T cell proliferation was quantitated by determining [3H]thymidine incorporation. In brief,
T cells, CD4+ or CD8* T cells (106 cells/ml) were cultured in a total volume of 200 A1 in
round-bottomed microwell plates at 37°C in a 5% C02, 95% air humidified atmosphere
and [3H]thymidine incorporation into DNA during 48-64 h of culture was determined in
a liquid scintillation counter. T cells were cultured in RPMI medium 1640 (catalogue no.
380-2400, Gibco Laboratories, Grand Island, NY) supplemented with 5% FCS (catalogue
no. 230-6140, Gibco Laboratories) and 0.1% gentamycin.
Measurement ofIntracellularfree Cat' Concentration.
￿
Intracellular free Cat` concentration of
T cells was determined using indo-1 (Molecular Probes, junction, City, OR), as described
(18). In brief, T cells were incubated with acetoxy-methyl ester of indo-1 (10 AM, 90 min,
37 °C), washed thrice, and resuspended at 106 cells/ml in the buffer medium. The ratio of
398 (violet)/482(blue) fluorescence ofindo-1 loaded T cells was measured'at designated time
intervals (R) and after lysis of cells with 1% Triton X-100 in the absence (Rm.) or presence
of 10 mM EGTA (Rmi), using a LS-5 Perkin-Elmer spectrofluorometer (Perkin-Elmer, Long
Island, NY). Cat* concentration was calculated using the formula: [Ca2'] = Kd x (R -
Rmin)/(Rm. + R) x sf2/sb2, where Kd is the dissociation constant (250 nM) and sf2/sb2 is the
ratio of the blue fluorescence intensity of the Ca2+-free and bound dye, respectively (18).
Detection ofIL-2 Gene Activation by Polymerase Chain Reaction (PCR).
￿
A new methodology,
reverse transcription followed by PC R (20), was utilized for the detection ofWRNAencoding
IL-2 . In brief, totalcellular RNA, isolated from T cells by guanidinium isothiocyanate/cesium
chloride method, was reverse transcribed into cDNA with 0.1 p.g/ml oligo(dT) primers and
200 U ofMoloney murine leukemia virus (M-MLV) reverse transcriptase (Bethesda Research
Corp., Bethesda, MD). The first strand cDNA copies were then amplified (30 cycles) with
either an IL-2 sequence specific primer pair (5'-CCTCTGGAGGAAGTGCTAAA-3' and 5'-
ATGGTTGCTGTCTCATCAGC-3') or o fl-actin sequence specific primer pair (5'-GTGG-
GCCGCTCTAGGCACCA-3'and 5'-TGGCCTTAGGGTGCAGGGGG-3') and Thermus
aquaticus DNA polymerase (Taq polymerase, Perkin-Elmer/Cetus Corp.), using a DNA
thermal cycler (Gene Machine; USA/Scientific Plastics, Ocala, FL) . The amplification profile
consisted of denaturation at 95°C for 45 s, primer annealing at 55°C for 1 min, and exten-
sion at 72°C for 1 min. The PCRgenerated products were fractionated by agarose gel elec-
trophoresis, and validated by the predicted size of the amplified cDNA fragments and by
restriction enzyme analysis.
Results
Synergismbetween mAbs Directed at the 71C'RandCD2Antigen.
￿
We examined whether
antiTCR1 and anti-CD2 mAbs are synergistic in promoting T cell proliferation.
This experimental approach was prompted by: (a) the observation that the mito-
genic activity of antiTCR1, a mAb that reacts with a framework determinant of
CD3/TCRa/a for antigen, is fullydependent upon the presence ofmonocytes (15-17),
and (b) our earlier demonstration that the crosslinked anti-CD2 can function as an
effective substitute for monocytes in oxidative mitogenesis (14).
Fig. 1 illustrates that OKT11, a prototypic mAb directed at the SRBC-binding
epitope of CD2 antigen (21), and antiTCRl are indeed synergistic in promoting
T cell proliferation: [sH]thymidine incorporation was only 1,395 t 501 cpm/cul-
ture with T cells incubated alone, and it increased significantly to 102,070 t 7,733
cpm/culture when T cellswere simultaneously signaled with antiTCR1 and OKT111968 CROSSLINKAGE OF TCRa/S HETERODIMER WITH THE CD2 ANTIGEN
(mean t SEM, n = 8, p < 0.0001, ANOVA). It is important to notethat the marked
proliferative response is absolutely dependent upon crosslinking ofantiTCR1 with
OKT11 and that neither the combined presence of soluble phase antiTCR1 and
OKT11 nor the crosslinking of antiTCR-1 alone or crosslinking of OKT11 alone
promotes T cell proliferation (Fig. 1 A).
Several additional features ofthe synergism between antiTCRl and OKT11 are
alsoillustratedin Fig. 1: (a)specificity ofsynergism: whereasantiTCR1 andOKT11
are synergistic, neither mAb is synergistic with soluble phase or crosslinked anti-
Leu-1 (anti-CD5) mAb (Fig. 1 B), (b)theneed for crosslinkingantiTCR1withOKT11:
whereas crosslinking antiTCRl with OKTll induces marked proliferation, selec-
tive crosslinking ofantiTCR1 (with affinity-purified antibodies specific for mouse
IgG1) fails to induce significant proliferation ofT cells treated with soluble phase
OKT11, and selective crosslinking ofOKT11 (with affinity-purified antibodies specific
for mouse IgG2a) fails to elicit marked proliferation ofT cells treated with soluble
phaseantiTCR1. Furthermore, selectivebutindependentcrosslinkingofantiTCR1
and OKT11 does not induce T cell proliferation (Fig. 1 C), and (c) dose-response
characteristics: the magnitude ofT cell proliferation elicited with crosslinked anti-
TCR1 and OKT11 is dependent upon the concentrations of antiTCR1 as well as
OKT11 (Fig. 1, D and E).
Synergism between F(ab')2 Fragments ofmAbs Directed at the TCR and CD2 Antigen.
￿
In
a fashion analogous to the signaling activity of intact antiTCR1 and OKT11,
F(ab')2 fragments of antiTCR1 and OKT11 were clearly synergisticin stimulating
T cells. Fig. 1 F illustrates the marked proliferation resulting from stimulating T
cells with F(ab')2 antiTCR1, F(ab')2 OKT11, and F(ab')2 rabbit anti-mouse IgG.
Fig. 1 Fshows also that neither the combined presence ofsoluble phase F(ab')2 anti-
TCR1 and F(ab')2 OKT11 nor crosslinking of F(ab')2 antiTCRl alone or F(ab')2
OKTll alone induces marked proliferation of T cells. The stimulation indices
([3H]thymidine incorporation of treated T cells/[3H]thymidine incorporation ofun-
treated T cells) were 137 with T cells treated with F(ab')2 antiTCR1 (0.25 kg/ml),
F(ab')2 OKT11 (0.5 Wg/ml), and F(ab')2 rabbit anti-mouse IgG (RaM IgG 2.5
Wg/ml); 1.3 with Tcells treated with crosslinked F(ab')2 OKT11 alone; 1.2 with T
cells treated with crosslinked F(ab')2 antiTCR-1 alone; and 1 .6 with T cells treated
with soluble phase F(ab')2 OKTll and F(ab')2 antiTCR1.
The magnitude ofT cell proliferationwasinfluenced notonlyby the relative con-
centrations ofF(ab')2 fragments of RaM IgG (Fig. 1 F) but also by the concentra-
tions of F(ab')2 fragments ofmAbs. For example, treatment ofT cells with F(ab')2
OKT11 (1.0 lAg/ml), F(ab')2 RuM IgG (2.5 ttg/ml), and 0.06, 0.125, 0.25, or 0.50
Wg/ml of F(ab')2 antiTCR-1 resulted in stimulation indices of 8, 31, 48, and 90,
respectively.
Anti-MR-1 and Anti-CD2 Are Synergistic in Inducing Proliferation of CD4' T Cells and
CD8' T Cells. Data summarized in Fig. 1 demonstrate that the crosslinkage of
TCRwithCD2 antigen promotes T cellproliferationindependentofco-stimulatory
signals (e.g., accessory cells, exogenous cytokines or phorbol esters). It was of in-
terest to determine whether this novel method of activation is effective in each of
the two major subsets of T cells, the CD4' and CD8' T cells.SUTHANTHIRAN
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FIGURE 1 .
￿
Synergism and unique aspects of signalingT cells with antiTCR-1 and anti-CD2
mAbs. HighlypurifiedhumanT cells (200,000 cells/200 Al) were incubated with antibodies shown
and the resultant proliferation was quantified (cpm, mean t SEM, n = 3-8) by determining
[3H]thymidine incorporation during 48-64 hofculture. Concentrations of reagents (panelsA-C) :
antiTCR1, 0.125 ,ug/ml ; OKTI1, 0.5 hg/ml ; anti-Leu-1, 0.5 pg/ml ; and gaM IgG specific for
mouse IgG, IgGl, or IgG2a, 5.0 Rg/ml. (D) Treatment ofT cells : (O) antiTCR-1 alone; (")
antiTCR-1 + gaM IgG (5 .0 jig/ml) ; (p) anti-TCR-1 + OKT11 (0 .5 14g/ml) ; (/) anti-TCR-1
+ OKT11 (0 .5 wg/ml) + gaM IgG (5.0 wg/ml) . (E) Treatment of Tcells: (O) OKT1I alone ;
(") OKT11 + gaM IgG (5 .0 P ,g/ml); (O) OKT11 + anti-TCR-1 (0.125 Irg/ml) ; (/) OKT11
+ antiTCR1 (0.125 Ag/ml) + gaM IgG (5.0 ug/ml) . (F) Treatment ofTcells : (O) none ; ([])
F(ab')2 RaM IgG ; (/) F(ab')2 OKT11 + RaMIgG; (") F(ab')2 anti-TCR-1 + RaMIgG; (A) :
F(ab')2 antiTCR-1 + F(ab')2 OKT11 ; (") F(ab')2 antiTCR-1 + F(ab')2 OKT11 + F(ab')2 RuM
IgG [F(ab')2 OKT11 : 0.5 pg/ml, F(ab')2 antiTCR1: 0.25 wg/ml] .
Crosslinked antiTCR1 and anti-CD2 did induce significant proliferation ofhighly
purified CD4+ subset and the CD8+ subset of T cells . AntiTCR1 or anti-CD2,
however, did not synergize with anti-CD4 or anti-CD8 mAbs and induce prolifera-
tion, under similar experimental conditions. The stimulation indices ([3H]thymi-
dine incorporation ofCD4+ or CD8+ T cells treated with crosslinked mAbs/[3H]thy-
midine incorporation of untreated CD4+ or CD8+ T cells) were 264, 4, 1.4, and
0.7 when CD4+T cells were treatedwith crosslinked antiTCR1 (0.125 Rg/ml) and1970 CROSSLINKAGE OF TCR-a/0 HETERODIMER WITH THE CD2 ANTIGEN
anti-CD2 (OKT11, 0.5 hg/ml), crosslinked antiTCR1 and anti-CD4 (OKT4A, 0.5
wg/ml), crosslinked anti-CD2 andanti-CD4 (OKT4A), or crosslinked anti-CD2 and
anti-CD4(OKT4, 0.5 ug/ml), respectively. The stimulationindices were 225, 2, and
1 when CD8+ T cells were treated with crosslinked antiTCR1 and anti-CD2, cross-
linked antiTCRl and anti-CD8 (OKT8, 0.5 ttg/ml), or crosslinked anti-CD2 and
anti-CD8 mAbs, respectively. Also, simultaneous but independent crosslinking of
TCR and the CD2 antigen on the surface ofCD4+ Tcells or CD8+ Tcells did not
result inmarked proliferation ofeither subset: the stimulation indices were only 0.8
and 1.3 when CD4+ T cells and CD8+ T cells, respectively, were treated with anti-
TCR-1 (0.125 ug/ml), OKT11 (0.5 tag/ml), gaM IgGl and gaM IgG2a (2.5 ttg/ml,
each). Thus, crosslinkage ofTCR with CD2 antigen, and not simultaneous but in-
dependent crosslinking ofTCR and CD2 antigen or crosslinking ofTCR or CD2
antigen with the CD4 orthe CD8 antigen, is a sufficient stimulus for the induction
of proliferation of normal human CD4+ or CD8+ T cells.
Effects of Crosslinkage of 71CR and/or CD2Antigen on Ca21 Mobilization.
￿
An increase
in the concentration ofintracellular free Cat+ is considered to be an early obliga-
tory event for T cell proliferation (22, 23). Given that crosslinkage of TCR with
the CD2 antigen promotes T cell proliferation and selective crosslinkage of TCR
or CD2 antigen does not, effects ofcrosslinking of antiTCR1 with 0KT11 as well
as effects ofselective crosslinking ofantiTCR1 and of0KT11 on intracellular Ca2+
homeostasis were determined.
Fig. 2 shows a rapid and marked increase in the concentration of intracellular
free Cat' by crosslinking antiTCR1 with OKT11: intracellular free Cat+ concen-
tration increased fromaprecrosslinked value of201 t 8 nMto apeak valueof 1,235
t 63 nM following the addition of goat anti-mouse IgG to T cells pretreated with
antiTCR1 and 0KT11 (mean t SEM, n = 6, p < 0.0001, ANOVA).
Selectivecrosslinking ofantiTCR1 orOKTll, in the presence ofreciprocal mAb
in soluble phase, also resulted in an increase in the concentration of intracellular
free Cat+. However, the magnitude of increase and the kinetics of increase found
with selectivecrosslinking were distinctly different fromthat found withcrosslinking
ofOKT11 with antiTCRl. As illustrated in Fig. 2, the peak intracellular Cat+ con-
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FIGURE 2.
￿
Calcium mobilization from cross-
linked anti TCR1 and/or OKT11. Intracellular
free calcium concentrationwas determinedwith
indo-1 loaded T-cells (106 cells) as described
in Materials and Methods. AntiTCRl (0.125
pg/ml) and OKT11 (0.5 Wg/ml) were added
to Tcell after determining the resting Tcell
calcium concentration; the mAbs were cross-
linked with gaM IgG ("), gaM specific for
IgGl (/) or IgG2A (A--- A). Results
(mean t SEM) from six consecutive experi-
ments (concentration of crosslinking reagent:
17
￿
5.0 ug/ml).SUTHANTHIRAN
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centrationswere 421 t 46 nM and 635 t 58nMwithselective crosslinkingofOKT11
or antiTCR1, respectively, in the presence of reciprocal mAb in soluble phase as
compared with 1,235 t 63 nM following crosslinkage ofantiTCR1 with OKT11
(p<0.0001, ANOVA). The peak concentration was reached rapidly by crosslinking
antiTCR1 with OKT11 or by selective crosslinking ofantiTCR1 alone, and was
reached slowly by selective crosslinking ofOKT11. Asustained increase in the con-
centration ofCat' above the precrosslinked Cat+ value was evident by crosslinking
antiTCR1 and OKT11 or by selective crosslinking ofOKT11, and not from selec-
tive crosslinking ofantiTCR1. Thus, crosslinkingofantiTCR1 andOKTll resulted
in a Cat+ mobilization profile that included the rapid increase in the Ca
21 levels
found with selective crosslinking of antiTCR1 alone and the sustained increase
resulting from selective crosslinking of OKT11 alone.
E ffects offulators ofProteinKinase C (PKC) on the Signaling of T Cells by Crosslinkage
of7LR with'-theCD2Antigen. Ca2+ and PKC activation participate in signal trans-
duction in a variety ofeukaryotic cells (24, 25). Having documented Cat' mobili-
zation by crosslinking the TCR with the CD2 antigen, we investigated the role of
Ca
2+ mobilization and PKC activation in the transduction of signals initiated by
crosslinking the TCR with the CD2 antigen. The contribution of Ca
2+ was exam-
ined with EGTA, and that ofPKC activation with direct or competitive inhibitors
of PKC.
Tcell proliferation induced bycrosslinking antiTCR1 (0.125 pcg/ml) with OKT11
(0.5 Ag/ml) was inhibited by EGTA: dose-response experiments revealed that the
half-maximal inhibitory concentration (IC5o) was 0.28 mM. The compound H-7,
a derivative of isoquinolinesulfonamide and a competitive inhibitor of PKC (26),
inhibited T cell proliferation and the IC5o was 0.019 mM. Staurosporine, a
microbial alkaloidand adirect inhibitor ofPKC (27), also mediated marked inhibi-
tion and the IC5o was 0.003 mM. An additional compound, K-252a, a competitive
inhibitor of PKC whose mechanism of action is similar to that of compound H-7
but witha greater potency(28), also inhibited T cell proliferation induced bycross-
linkage of antiTCR-1 with OKT11 and the IC5o for K-252a was 0.05 /AM.
TCellProliferationInducedby Crosslinkage of7L'R with the CD2Antigen Is IL-2Depen-
dent. IL-2-dependent as well as IL-2-independent pathways of T cell activation
havebeen reported (29-32). Wethereforedetermined whether crosslinkingtheTCR
with the CD2 antigen results in transcriptional activation and translation ofthe gene
for IL-2. We also examined whether IL-2 receptor a (a subunit of IL-2 receptor
that facilitates high-affinity binding of IL-2) is induced and whether successful in-
teraction between IL-2 and its receptor is required for T cell proliferation elicited
by crosslinking the TCR with the CD2 antigen.
Agarose gel electrophoretic analysis of PCR products generated with IL-2 se-
quence-specific primers or with fl-actin sequence-specific primers and Taq poly-
merase are illustrated in Fig. 3. It is evident that: (a) T cells signaled with cross-
linked antiTCR-1 and OKT11 express the IL-2 gene (lane 4); (b) crosslinking of
antiTCR1 alone, OKT11 alone or simultaneous but independent crosslinking of
antiTCR1 and ofOKT11 does not result in IL-2 mRNA accumulation (lanes 2,
3, 5 and 6), and (c) a-actin mRNA (control mRNA) expression is similar in mAb
treated or untreated T cells (lanes 1-6). In accordance with the data shown in Fig.
3, cell-free supernatants, obtained from T cells treated with crosslinked antiTCR11972 CROSSLINKAGE OF TCRa//3 HETERODIMER WITH THE CD2 ANTIGEN
FIGURE 3 .
￿
Detection of IL-2
gene activation with thePCR.
Total cellular RNA, isolated
from treated or untreated T
cells, was reverse transcribed
into cDNA with oligo (dT)
primers and M-MLV reverse
transcriptase . The first strand
cDNA was amplified (30 cycles)
with an IL-2 sequence-specific
primer pair or with a 0-actin-
specific primer pair and Taq
polymerase . The amplified PCR
products were fractionated by
1.5% agarose gel electrophore-
sis using Tris-acetate EDTA
buffer (pH 8.0), stained with
ethidium bromide, and vali-
dated by the predicted size of
IL-2 cDNA fragment (149 by
for IL-2) and 0-actin cDNA
fragments (350 bp). Mse I re-
striction enzyme digestion of
IL-2 cDNA generated the expected 61 and 88 by fragments . (Lane 1)T + 0, (lane 2)T + antiTCR-1
+ gaM IgG, (lane 3) T + OKT11 + gaM IgG, (lane 4) T + antiTCR-1 + OKTII + gaM IgG,
(lane 5) T + antiTCR1 + OKTII gaM IgG2a and (lane 6) T + antiTCR1 + OKT11 + gaM
IgGl (antiTCR-1 : 0.25 wg/ml, OKTII : 0.5 hg/ml, gaM IgG, IgG2a or IgGl : 5.0 Irg/ml) . Arrows on
the right indicate 4 repeats of 123 by ladder in the marker (M lane .
and OKT11, induced marked proliferation of an IL-2-dependent cytotoxic T cell
line (33) .
Signaling ofT cells with crosslinked antiTCR1 andOKT11 resulted also in the
induction of IL-2 receptor u expression . FAGS analyses illustrating the synergism
between antiTCR1 andOKT11 in the elicitation of IL-2 receptor a expression are
summarized in Fig . 4 .
In a fashion homologous to physiologic signaling ofT cells, the proliferative re-
sponse elicited by crosslinkingTCRwith theCD2 antigen wasdependent upon suc-
cessful interactions betweenIL-2 and its receptor. As shown in Fig . 5, mAb directed
at IL-2 receptoru(anti-CD25 mAb) inhibitedT cell proliferation inducedwith cross-
linked antiTCR1 andOKT11 (26 < 0.001, ANOVA) . The inhibition resulting from
anti-CD25 mAbwas reversed, in aconcentration-dependent manner, by recombinant
IL-2 (Fig . 5, B-E).
Discussion
Results from this study demonstrate for the first time that crosslinkage of CD3/
TCRa//3 complex with theCD2 antigen on the surface of CD4+ or CD8+ T cells
results in their activation independent ofcostimulatory signals (e.g., accessory cells,
exogenous lymphokines, or phorbol esters). Furthermore, crosslinkage ofTCR with
the CD2 antigen elicits an activation cascade that is homologous to physiological
antigenic signaling ofT cells with respect to : (a) Cat + mobilization andPKC acti-
vation forcell-surface signal transduction, (6) transcriptional activation andtransla-
tion of the gene for IL-2, and (c) utilization of IL-2 and IL-2 receptor pathway for
the proliferative response.SUTHANTHIRAN
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FIGURE 4 .
￿
FRCS analysis ofT cells for IL-2 receptor a expression. T cells (106 cells) were in-
cubated with various agents for 16 h at 37°C in a 5% C02/95% air humidified atmosphere ;
the cells were then labeled with PE-conjugated anti-CD25 mAb or with PE-conjugated isotypic
IgGl controlmAb. The percentage ofT cells positive for IL-2 receptor a (shown in each panel)
was determined by analysis ofimmunofluorescence histograms using EpicC multidata acquisi-
tion and display systems, software version 3 .1 . Nonspecific fluorescence (dark lines) found with
the isotypic controlmAb is also shown . (A) T cells + antiTCR 1 (0.125 Wg/ml) + OKTll (0.5
F+g/ml) + gaM IgG (5.0 gg/ml) ; (B) T-cells + none ; (C) T cells + antiTCR 1 (0.125 pg/ml)
+ gaM IgG (5.0 pg/ml); (D) T cells + 0 .5 wg/ml OKT11 + gaM IgG (5.0 Rg/ml).
Several features ofourexperimental design are worthy of emphasis: First, normal
human restingT cells andT cell subsets and not abnormal or preactivated T cells
were used in our study. This approach represents a significant physiological advan-
tage in light of the differential signaling requirements ofT cell lines, clones, or hy-
bridomascompared with restingTcells (34-37) . Second, mAbs directed at a frame-
work determinantof theCD3/TCRcdOcomplex rather than mitogenic lectinswere
used . This strategy permits the study of the signaling activity of a cell-surface mole-
cule involved in physiological antigen signal transduction . It is important to note
that antiTCR1, at concentrations used in our study, reacts only with the T cells
expressing thea//3heterodimerof theTCR and not with T cells thatdo not express
this heterodimer (38) . Third, mAbs directed at theCD2 antigenwere used to generate
the obligatory accessory signal in our investigation . Given that the CD2 antigen
is expressed on all peripheral blood T cells, our approach has the potential to un-
cover signaling pathways operative in theCD4 as well as theCD8 subset of normal
human T cells . Fourth, mAbs directed at the SRBC-binding epitope (CD2 .1 epi-
tope) of theCD2 antigen were used herein to generate the stimulatory signal . This
is significant in view of earlier suggestions that theCD2.1 epitope generates inhibi-
tory signals and that the CD2.2 and CD2.3 epitopes need to be engaged in order
to generate stimulatory signals (6-9). Moreover, the CD2.1 epitope, unlike some
of the other epitopes of theCD2 antigen (CD2.3 or 9-1), is constitutively expressed
on restingT cells and thus has the potential to initiate and/or participate in the very
first event obligatory forT cell activation . Fifth, activation was accomplished in our1974 CROSSLINKAGE OF TCRa/0 HETERODIMER WITH THE CD2 ANTIGEN
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FIGURE 5. Effects of anti-
CD25 mAbs and/or recombi-
nant IL-2 on T cell prolifera-
tion. T cells (200,000 cells/200
Al)were activated by crosslink-
ing antiTCRl (0.125 pg/ml)
with OKT11 (0.5 pg/ml), and
proliferation was measured by
determining 13H]thymidine in-
corporation during 48-64 h of
culture. Concentration-depen-
dent inhibition foundwith anti-
CD25 mAb is shownin A. The
ability of recombinant IL-2 to
reverse anti-CD25mAb-associ-
ated inhibition in B-E. Results
(mean t SEM) found in three
consecutive experiments.
study in the absence of co-stimulatory agents (e.g., feeder cells, exogenous IL-2 or
tumor promoters). These additional stimuli are mandatory for T cell proliferation
induced with mAb combinations such as CD2 - D66 + CD2 9.6/T11t (39), CD3-
BMA030 + mAb directed at T cell surface antigens (40, 41), or CD3-RW24B6 +
CD4-19 Thy 5D7 or CD8-21 Thy 2D3 (42).
Signaling by Crosslinkage of 7CR with the CD2Antigen.
￿
An important requirement
for the induction of proliferation of normal human T cells demonstrated herein is
that theTCRshould be crosslinked with theCD2 antigen: selectiveor simultaneous
but independent crosslinking of these cell surface molecules is insufficient to elicit
the proliferative response. Furthermore, crosslinkage of TCR with CD2 but not of
either antigen with CD4 or CD8 antigen elicits marked proliferation (ofthe corre-
sponding subset) independent of co-stimulatory signals. This differential signaling
potential of T cell surface molecules, viewed especially in the light of observations
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of others that crosslinking CD4 or CD8 with CD3 antigen induces T cellprolifera-
tion onlyin the presence ofexogenous IL-2 orphorbol esters (40, 42), suggests that:
(a) crosslinking the TCR with the CD4 or CD8 antigen generates signals that are
sufficient only forthe induction ofT cellcompetence to growth factors such as IL-2
but not for IL-2 production and/or T cell's progressionthroughthe entire cell-cycle,
and(b) crosslinkage ofTCRwith the CD2 antigen generatesinstructive signals that
are adequate not only for the acquisition ofcompetence but also for the production
of IL-2 and the progression ofT cells through the entire cell cycle.
Participation of Ca" and PKC in Signal Transduction.
￿
A unifying theme for the
transmembrane regulation ofcellular functions is that Ca2+ mobilization and PKC
activation function as synergistic intracellular signals, (22-25, 43). Indeed, cross-
linkage of the TCR with the CD2 antigen resulted in a marked and sustained in-
crease in intracellular free Cat' levels. Our finding that a sustained increase in Cat'
is required for the full activation ofnormal human T cells is reminiscent ofthe ob-
servation that a sustained but not a transient increase in intracellular free Ca2+ is
associated with the expression ofthe IL-2 gene inJurkat T cell line (44). Our addi-
tional observations that EGTA and regulators ofPKC are inhibitory are consistent
with Caz+ mobilization and PKC activation participating in the transduction of
signals generated by crosslinkage of TCR with the CD2 antigen.
Utilization of an Operational IL-2 System.
￿
Antigen-induced T cell proliferation is
dependent upon the expression ofreceptors for IL-2, production ofIL-2, and suc-
cessful interactionbetween IL-2 andits receptors (29, 30). Evidenceforan interleukin-
independent pathway for human lymphocyte proliferation however, has also been
presented (31, 32). Our data that crosslinkage of TCR with the CD2 antigen in-
duces IL-2 gene activation and IL-2 receptor expression, and that mAb directed
at the IL-2 receptor inhibits T cell proliferation, support the contention that T cell
proliferationinduced bythis novel approach isdependentupon an operational IL-2
system, and is homologous to physiological antigen-dependentTcell proliferation.
ANovelModelforAntigen-dependent TCell Signaling.
￿
Aunifyingtheme hasemerged
in which T cells view antigens in the context ofMHC gene products expressed on
antigen-presenting (accessory) cells. T cell surfaceproteins, in addition totheTCR,
that contribute totheinformativeT cell-accessory cell interactions, however, have re-
mained an enigma despite the paradigm that theCD4 and CD8 molecules function
as associative recognition/restrictionelementsforthe MHC geneproductsexpressed
on the surface of accessory cells.
Based on our current as well as earlier investigations, it is possible to conceptu-
alize a novel model for antigen-dependent activation of T cells. As schematized in
Fig. 6, instructiveT cell-accessory cell interactions might proceed not onlyvia mo-
lecular contacts between the TCR and the MHC-peptide but also viathe CD2 an-
tigen and the LFA-3 and/or other sites on accessorycells (step 1). These cell-surface
molecular interactions then, lead to the coclustering ofthe TCR with the CD2 an-
tigen(step 2). Theantigen- and accessorycell-induced associationbetweentheTCR
and the CD2 antigen is necessary for the optimum generation of second messenger
molecules (Ca2+, DAG, etc.) and transcriptional activation and translation ofgenes
(IL-2, IL-2 receptor, etc.) responsible for the antigen-dependent clonal expansion
ofnormal human T cells (step 3). A critical observation that supports the concept
formulated herein is our earlier demonstration that the anti-CD2 mAb (the same1976 CROSSLINKAGE OF TCR-a//3 HETERODIMER WITH THE CD2 ANTIGEN
Step 1 : Antigen dependent T-cell- Accessory cell interaction
T-cell
TCR/CD3
CD2 antigen
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Step2 : Antigen and accessorycell dependent co-clustering ofTCR/CD3 and CD2antigen
Step 3: Generation of second messengers and gene activation
Cat' PKC rPIP2 -
T-cell program
IL-2and IL-2R
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Antigen
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FA-3and/or
other sites
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FIGURE 6. Schema for anti-
gen-dependentTcell signaling.
Antigen-dependent T cell-ac-
cessory cell interactions involve
notonly molecularcontacts be-
tweenCD3/TCR-a/,6 complex
and the antigenic peptide (")
viewed in thecontext ofMHC
antigens on accessory cells but
also physical associations be-
tween the CD2 antigen with
LFA-3 and/or other sites (step
1). These molecular contacts
lead to the redistribution and
coclustering oftheTCRandthe
CD2 antigen on the surface of
Tcells (step 2). This cocluster-
ingis required fortheoptimum
generation ofsecond messenger
moleculesandtheactivation of
genes responsible for antigen-
dependent clonal expansion of
T cells (step 3).
mAb used in this investigation) prevents clustering between T cells and accessory
cells; an important additional supportive observation from our laboratory is that
anti-CD2 (soluble phase) inhibits Tcell proliferation only when the obligatory co-
stimulatory signal is provided with accessory cellsbut not whenTPA (accessorycell
substitute)provides theaccessorysignal (13, 14). Elegant datashowingthat antigen-
dependent IL-2 productionis enhanced by the expression ofCD2 antigen in a mu-
rine T cell hybridoma (45) and that LEA-3, a natural ligand for CD2 antigen (46),
is mitogenic (47), are in accord withsome ofthe features ofthe minimal model for-
mulated here for the activation of normal human quiescent T cells.
Summary
Transmembranesignalingofnormal humanTcells wasexplored withmAbsdirected
at TCR, CD2, CD4, CD5, or CD8 antigens and highly purified CD4+ T cells and
CD8+ T cells. Our experiments explicitly show that: (a) crosslinkage of TCR with
the CD2 antigen, and not independent crosslinking of TCR and of CD2 antigen
or crosslinking ofeither protein with the CD4 or CD8 antigen induces significant
proliferation independentofco-stimulatory signals (e.g., accessory cells, recombinant
lymphokines, or tumor promoter), (b) F(abr)2 fragments of mAb directed at the
TCR and F(abr)2 anti-CD2, crosslinked with F(abr)2 fragments ofrabbit anti-mouse
IgG, promote the proliferationofhighly purified Tcells, (c) a prompt and sustained
increase in intracellular free Cat+ concentration results from crosslinkage of TCR
with the CD2 antigen, (d) T cell proliferation induced by this novel approach is cur-
tailed by EGTA and by direct or competitive inhibitors ofPKC, (e) crosslinkage of
TCR with the CD2 antigen results in the transcriptional activation and translation
ofthe gene for IL-2 and in theexpression ofIL-2 receptor a (CD25), (f) anti-CD25SUTHANTHIRAN
￿
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mAbs inhibit T cell proliferation initiated by crosslinkage of TCR with the CD2
antigen, and recombinant IL-2 restores the proliferative response. Our first demon-
stration that crosslinkage ofTCR with the CD2 antigen induces proliferation ofnormal
human CD4+ T cells and CD8 + T cells, in addition to revealing a novel activation
mechanism utilizable by the two major subsets of T cells, suggest that the CD2 an-
tigen might be targeted for the regulation of antigen-specific T cell immunity (e.g.,
organ transplantation).
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